These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 27721259

  • 1. Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
    Shen C, Chen L, Fu J, Lin H.
    J Cancer Res Ther; 2016 Oct; 12(Supplement):72-75. PubMed ID: 27721259
    [Abstract] [Full Text] [Related]

  • 2. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
    Huang PY, Li Y, Mai HQ, Luo RZ, Cai YC, Zhang L.
    Oral Oncol; 2012 Oct; 48(10):964-968. PubMed ID: 22571922
    [Abstract] [Full Text] [Related]

  • 3. Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma.
    Xu S, Yu Y, Rong J, Hu D, Zhang L, Fu S, Yang H, Fan J, Yang L, Wu J.
    Oncotarget; 2017 May 09; 8(19):31355-31367. PubMed ID: 28404895
    [Abstract] [Full Text] [Related]

  • 4. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
    Wang D, Zhou J, Zheng J, Zhang J, Chen Y, Li W, Wang R.
    Cancer Biomark; 2018 May 09; 21(4):875-881. PubMed ID: 29439312
    [Abstract] [Full Text] [Related]

  • 5. Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy.
    Zhang Z, Jiang C, Hu L.
    Tumori; 2014 May 09; 100(3):328-32. PubMed ID: 25076246
    [Abstract] [Full Text] [Related]

  • 6. [Correlation between expression of ERCC1 and the treatment of cisplatin-based chemotherapy in local advanced nasopharyngeal carcinoma].
    Li W, Sun Q, Lu M.
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan 09; 29(2):144-6. PubMed ID: 25989663
    [Abstract] [Full Text] [Related]

  • 7. Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?
    Chan SH, Cheung FM, Ng WT, Choi CW, Cheung KN, Yiu KH, Lee AW.
    Int J Radiat Oncol Biol Phys; 2011 Apr 01; 79(5):1414-20. PubMed ID: 20605357
    [Abstract] [Full Text] [Related]

  • 8. Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?
    Aksoy A, Elkiran ET, Harputluoglu H, Dagli AF, Isikdogan A, Urakci Z.
    J Cancer Res Ther; 2019 Apr 01; 15(3):550-555. PubMed ID: 31169219
    [Abstract] [Full Text] [Related]

  • 9. Correlation between ERCC1 expression and concurrent chemotherapy and radiotherapy in patients with locally advanced nasopharyngeal cancer.
    Liang R, Lin Y, Liu ZH, Liao XL, Yuan CL, Liao SN, Li YQ.
    Genet Mol Res; 2015 May 29; 14(2):5804-11. PubMed ID: 26125779
    [Abstract] [Full Text] [Related]

  • 10. Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.
    Liu T, Li Y, Song J, Li B, Wang R, Huang T, Qin Y.
    Cancer Control; 2024 May 29; 31():10732748241251562. PubMed ID: 38716503
    [Abstract] [Full Text] [Related]

  • 11. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
    Kim KH, Do IG, Kim HS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim DH, Ji SH, Park MJ, Lee J, Park SH, Kwon GY, Lim HY.
    APMIS; 2010 Dec 29; 118(12):941-8. PubMed ID: 21091775
    [Abstract] [Full Text] [Related]

  • 12. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
    Chen C, Wang F, Wang Z, Li C, Luo H, Liang Y, An X, Shao J, Li Y.
    Cancer Chemother Pharmacol; 2013 Aug 29; 72(2):315-22. PubMed ID: 23712330
    [Abstract] [Full Text] [Related]

  • 13. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.
    Lee HW, Hwang YH, Han JH, Choi JH, Kang SY, Jeong SH, Ann MS, Oh YT, Kim JH, Kim CH, Sheen SS.
    Oral Oncol; 2010 Mar 29; 46(3):209-13. PubMed ID: 20153243
    [Abstract] [Full Text] [Related]

  • 14. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
    Hua L, Chen S, Wei M, Shen Y, Long J, Lin Z, Meng Y, Guo C, Huang H, Tu X, Yao M.
    Cancer Biother Radiopharm; 2022 Feb 29; 37(1):2-10. PubMed ID: 33764811
    [Abstract] [Full Text] [Related]

  • 15. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P.
    Clin Cancer Res; 2007 Jul 01; 13(13):3855-9. PubMed ID: 17606717
    [Abstract] [Full Text] [Related]

  • 16. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N.
    J Thorac Oncol; 2007 Oct 01; 2(10):902-6. PubMed ID: 17909351
    [Abstract] [Full Text] [Related]

  • 17. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.
    Hui EP, Ma BB, Chan KC, Chan CM, Wong CS, To KF, Chan AW, Tung SY, Ng WT, Cheng AC, Lee VH, Chan SL, Loong HH, Kam MK, Leung SF, Ho R, Mo F, Ngan RK, Chan AT.
    Cancer; 2015 Aug 15; 121(16):2720-9. PubMed ID: 25946469
    [Abstract] [Full Text] [Related]

  • 18. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.
    Sun JM, Ahn MJ, Park MJ, Lee HY, Ahn JS, Lee S, Kang G, Han J, Son YI, Baek CH, Ahn YC, Park K.
    Int J Radiat Oncol Biol Phys; 2011 Jul 01; 80(3):655-60. PubMed ID: 21621119
    [Abstract] [Full Text] [Related]

  • 19. Is there relationship between excision repair cross-complementation 1 expression level and response to treatment and prognosis in an advanced stage lung cancer treated with cisplatin-based chemotherapy?
    Polat G, Yılmaz U, Anar C, Kömürcüoğlu B, Aydoğdu Z.
    Indian J Cancer; 2015 Jul 01; 52(3):277-80. PubMed ID: 26905109
    [Abstract] [Full Text] [Related]

  • 20. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.
    Hwang IG, Jang JS, Do JH, Kang JH, Lee GW, Oh SY, Kwon HC, Jun HJ, Lim HY, Lee S, Chi KC, Lee SJ.
    Cancer Chemother Pharmacol; 2011 Oct 01; 68(4):935-44. PubMed ID: 21298384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.